PATENT CLAIM ANALYSIS

Application Number: 16124111
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["424", "482000"]

Abstract:
Disclosed are pharmaceutical compositions comprising Compound I, having the formula: and an effective amount of sofosbuvir wherein the sofosbuvir is substantially crystalline. Also disclosed are methods of use for the pharmaceutical composition.

Claim (Index 60):
A method of treating hepatitis C in a human patient in need thereof comprising administering to the patient once daily a pharmaceutical composition, wherein the pharmaceutical composition comprises:\n a) about 200 mg of a solid dispersion comprising Compound I dispersed within a polymer matrix formed by copovidone, wherein the weight ratio of Compound Ito copovidone in the solid dispersion is about 1:1 and wherein Compound I is substantially amorphous having the formula: b) about 400 mg of substantially crystalline sofosbuvir having the formula: c) about 355 mg of microcrystalline cellulose; d) about 30 mg of croscarmellose sodium; and e) about 15 mg of magnesium stearate.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 97.0
- Lexical Diversity: 1.24138
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15393847', '15670283', '15282128', '15885630', '14563639']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7265550096681954
- 35 USC 102 Novelty (BERT): 0.507395786550087
- Combined Prediction Score: 0.7046390873563846
- Mean Citation Score: 216.272936
- Max Citation Score: 254.84079
- Similarity Product: 238.54510318274257

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test